# A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy

> **NCT01668017** · PHASE1 · TERMINATED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 26 (actual)

## Conditions studied

- Advanced Solid Tumors
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Pimasertib
- **DRUG:** Pimasertib
- **DRUG:** Pimasertib
- **DRUG:** Pimasertib
- **DRUG:** Pimasertib

## Key facts

- **NCT ID:** NCT01668017
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09-30
- **Primary completion:** 2015-05-31
- **Final completion:** 2015-05-31
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** The sponsor decided not to conduct the expansion part of trial (part 2)
- **Last updated:** 2017-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01668017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01668017, "A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01668017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*